The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

The biotech sector is entering 2026 with a positive outlook, characterized by reasonable valuations, robust oncology momentum ...

OverviewThe global NLP in healthcare & life sciences market is anticipated to expand at a CAGR of nearly 25% during the forecast period, fueled by widespread EHR adoption, rising interest in ...

A one-day national-level workshop on “Drug Designing, Molecular Docking and Simulations” was held today at the BRIC–Institute of Bioresources and Sustainable Development (IBSD), Takyelpat, ...

Ace Therapeutics recently launched in vivo efficacy testing services for IBD drug candidates. Ace Therapeutics, a preclinical ...

Taken together, these strands point in the same direction: CEOs and senior leaders must shift from an “AI productivity” ...

Gene editing has rapidly evolved into a transformative class of technologies that allow scientists to precisely insert, ...

TheFly reported on December 15 that Barclays raised its price target for TWST from $37 to $39 while maintaining an Overweight ...

While everyone agrees on the ethical imperative to reduce animal use, the challenge of widespread readiness will depend on partnership, proof, and continued development activities. Public perception ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...